Breast cancer
Conditions
Interventions
four cycles of therapy, administered every 3 weeks. Docetaxel (75 mg/m2) and Cyclophosphamide (600 mg/m2) are administered by intravenous infusion on day 1 in eacn cycle.
Sponsors
Gunma Breast Cancer Research Group 2 surgery
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Histologically diagnosed breast cancer without lymph node metastasis or with three and under lymph node metastasis. 2)Age 20 to 70 years 3)ECOG PS 0 to 2 4)Previous endocrine therapy or chemotherapy for breast cancer. 5)Required baseline laboratory parameters 6)Without severe complications,ischemia attack, uncontrolled congestive heart failure 7)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Patients who received previous endocrine therapy or chemotherapy 2)Severe drug allergic history 3)Inflammatory breast cancer 4)Bilateral breast cancer in same time 5)Severe complications 6)Active double cancer 7)Inflammation with fever up 8)Neurological problem 9)Pleural effusion or pericardial effusion 10)Symptomatic brain metastasis 11)Pregnancy 12)Severe edema 13)Interstitial lung disease, pulmonary fibrosis 14)Psychiatric disease 15)Doctors decision for excluion 16)Low risk in St. Gallen Conferences 2007 17)16 weeks or more after operation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety completion rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease free survival Overall survival | — |
Countries
Japan
Contacts
Public ContactNana Rokutanda
Gunma Breast Cancer Research Group 2 surgery (GBCRG-2surg) 01 Secretariat Division (Department of Thoracic Visceral Organ Surgery , Gunma University Graduate Scho
Outcome results
None listed